Anticoagulation Forum/LinkedIn
Sep 13, 2025, 13:36
Emerging Evidence on Long-Term Oral Anticoagulation After Provoked VTE: Insights from the HI-PRO Trial
Anticoagulation Forum shared on LinkedIn.
“Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
- Faculty:
Arthur Allen, PharmD, CACP – SALT LAKE CITY VA HEALTH CARE SYSTEM
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register today here.
Read more on Hemostasis Today.
-
Sep 14, 2025, 11:17Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
-
Sep 13, 2025, 13:32Beta Thalassemia Major After Splenectomy: Setareh Sheikhi Reports Striking nRBC Surge Reports Striking nRBC Surge
-
Sep 13, 2025, 13:26Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 14, 2025, 14:36Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
-
Sep 14, 2025, 12:37Ivan Budnik Highlights New Framework for Thrombus Resolution Analysis in Mouse IVC Stenosis Model
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 13:35Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
-
Sep 13, 2025, 13:20Giulia Simini: Our Review on the Hepatic Life Cycle of AAV is Now Available in JTH
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere
Sep 14, 2025, 04:16
Sep 13, 2025, 13:34